Is Relay Therapeutics Inc (RLAY) overvalued? · rev $10.0M
Relay Therapeutics Inc (RLAY) is a biotechnology company listed on NASDAQ.
This page asks whether Relay Therapeutics Inc (RLAY) looks expensive on cached numbers — not a short thesis.
Latest reported RLAY revenue for 2024-12-31 was $10.0M. Net income was -$337.7M. Revenue was down 60.8% from 2023-12-31 to 2024-12-31. RLAY currently screens at market cap $3.39B.
RLAY currently screens at market cap $3.39B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next RLAY 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the RLAY stock page for the full model, not this heading.
Not investment advice.